| Project/Area Number |
24791491
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKADA Mitsutoshi 金沢大学, 医学系, 講師 (20334774)
TANAKA Shingo 金沢大学, 医学系, 協力研究員 (40507084)
FUROTA Takuya 金沢大学, 大学病院, 医員 (20646690)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | glioblastoma / GSK3beta / グリオブラストーマ / 分子標的治療 |
|---|
| Research Abstract |
We focus on the glycogen synthase kinase 3beta,serine-threonine kinase family, demonstrated that inhibition of GSK3beta supresses proliferation and invasion of glioblastoma cells ,and increases the effect of anti-cancer drugs synergistically. In the study using a mouse tumor model, we demonstrated tumor growth inhibitory effect of GSK3be-ta inhibition in vivo. We reported that GSK3be-ta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. In addition, using existing drugs with GSK3be-ta inhibitory effect, we conducted clinical trial for recurrent glioblastoma.
|
